{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T10:48:50Z","timestamp":1788518930616,"version":"build-2803163510"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T00:00:00Z","timestamp":1712534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T00:00:00Z","timestamp":1712534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Our study aimed to provide real-world evidence on the treatment patterns, effectiveness and safety of canakinumab in France in Familial Mediterranean Fever (FMF), Mevalonate Kinase Deficiency (MKD), and Tumor necrosis factor Receptor Associated Periodic Syndrome (TRAPS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study used the JIR cohort, a multicentre international registry created in 2013 to collect data on patients with juvenile inflammatory rheumatic diseases. French patients diagnosed with FMF, MKD or TRAPS and treated with canakinumab were included in this study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>31 FMF, 26 MKD and 7 TRAPS patients received canakinumab during the study period. Most of them initiated canakinumab at the recommended dose of 2\u00a0mg\/kg or 150\u00a0mg, but less than half of FMF and MKD patients initiated it at the recommended frequency (every 4 weeks). Two years after initiation, the rate of patients still on treatment was 78.1% in FMF, 73.7% in MKD, and 85.7% in TRAPS patients. While the dose per injection remained globally the same over the course of the treatment, some adjustments of the dose intervals were observed. Six patients had a severe adverse event reported. Of those, three were possibly related to canakinumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This interim analysis showed a good maintenance of canakinumab treatment 2 years after initiation and confirmed its safety profile in real-life practice in France in patients diagnosed with FMF, MKD and TRAPS. The high variety of dose and interval combinations observed in canakinumab treated patients let suppose that physicians adapt the posology to individual situations rather than a fixed treatment plan.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13075-024-03316-7","type":"journal-article","created":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T02:02:14Z","timestamp":1712541734000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Canakinumab treatment real world evidence in 3 monogenic periodic fever syndromes in 2009\u20132022: an interim analysis using the French JIR cohort database"],"prefix":"10.1186","volume":"26","author":[{"given":"Isabelle","family":"Kon\u00e9-Paut","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Georgin-Lavialle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Belot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magali","family":"Jover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathilde","family":"Pouriel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Lacoin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Pillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Hentgen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,8]]},"reference":[{"key":"3316_CR1","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/B978-0-323-24145-8.00047-8","volume-title":"Textbook of Pediatric Rheumatology","author":"KS Barron","year":"2016","unstructured":"Barron KS, Kastner DL. Periodic fever syndromes and other inherited autoinflammatory diseases. In: Petty RE, Laxer RM, Lindsey CB, Wedderburn LR, editors. Textbook of Pediatric Rheumatology. 7th ed. Philadelphia: Elsevier; 2016. pp. 609\u201326.","edition":"7"},{"key":"3316_CR2","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1038\/ni.3777","volume":"18","author":"K Manthiram","year":"2017","unstructured":"Manthiram K, Zhou Q, Aksentijevich I, Kastner DL. The monogenic autoinflammatory diseases define new pathways in human innate immunity and inflammation. Nat Immunol. 2017;18:832\u201342.","journal-title":"Nat Immunol"},{"key":"3316_CR3","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1056\/NEJMoa1706314","volume":"378","author":"F De Benedetti","year":"2018","unstructured":"De Benedetti F, Gattorno M, Anton J, et al. Canakinumab for the treatment of autoinflammatory recurrent fever syndromes. N Engl J Med. 2018;378:1908\u201319.","journal-title":"N Engl J Med"},{"key":"3316_CR4","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.revmed.2018.02.005","volume":"39","author":"S Georgin-Lavialle","year":"2018","unstructured":"Georgin-Lavialle S, Rodriguez F, Hentgen V, Fayand A, Quartier P, Bader-Meunier, Bachmayer C, Savey L, Louvrier C, Sarrabay G, Melki I, Belot A, Kon\u00e9-Pault I, Grateau G. Panorama Des maladies auto-inflammatoires. La Revue De Med Interne. 2018;39:240\u201355.","journal-title":"La Revue De Med Interne"},{"issue":"23","key":"3316_CR5","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1056\/NEJMe0811014","volume":"360","author":"Dinarello","year":"2009","unstructured":"Dinarello. Interleukin-1\u03b2 and the Autoinflammatory diseases. N Engl J Med. 2009;360(23):2467\u20139.","journal-title":"N Engl J Med"},{"issue":"8","key":"3316_CR6","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1136\/jmedgenet-2017-105216","volume":"55","author":"ME Van Gijn","year":"2018","unstructured":"Van Gijn ME, Ceccherini I, Shinar Y, Carbo EC, Slofstra M, Arostegui JI, et al. New Workflow for classification of genetic variants\u2019 pathogenicity Applied to Hereditary Recurrent fevers by the International Study Group for Systemic Autoinflammatory Diseases (INSAID). J Med Genet. 2018;55(8):530\u20137.","journal-title":"J Med Genet"},{"issue":"4","key":"3316_CR7","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1136\/annrheumdis-2015-208690","volume":"75","author":"S Ozen","year":"2016","unstructured":"Ozen S, Demirkaya E, Erer B, Livneh A, Ben-Chetrit E, Giancane G, Ozdogan H, Abu I, Gattorno M, Hawkins PN, Yuce S, Kallinich T, Bilginer Y, Kastner D, Carmona L. EULAR recommendations for the management of familial mediterranean fever. Ann Rheum Dis. 2016;75(4):644\u201351.","journal-title":"Ann Rheum Dis"},{"key":"3316_CR8","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1136\/annrheumdis-2021-221801","volume":"81","author":"M Romano","year":"2022","unstructured":"Romano M, et al. The 2021 EULAR\/American College of Rheumatology points to consider for diagnosis, management and monitoring of the interleukin-1mediated autoinflammatory diseases: cryopyrin-associated periodic syndromes, tumour necrosis factor receptor-associated periodic syndrome, mevalonate kinase deficiency, and deficiency of the interleukin-1 receptor antagonist. Ann Rheum Dis. 2022;81:907\u201321.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"3316_CR9","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1002\/acr.23083","volume":"69","author":"I Kone-Paut","year":"2017","unstructured":"Kone-Paut I, Quartier P, Fain O, Grateau G, Pillet P, Le Blay P, Bonnet F, Despert V, Stankovic-Stojanovic K, Willemin L, Qu\u00e9r\u00e9 S, Reigneau O, Hachulla E. Real-world experience and impact of Canakinumab in Cryopyrin-Associated Periodic Syndrome: results from a French Observational Study. Arthritis Care Res (Hoboken). 2017;69(6):903\u201311.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"2","key":"3316_CR10","doi-asserted-by":"publisher","first-page":"123","DOI":"10.36469\/9860","volume":"1","author":"HJ Lachmann","year":"2013","unstructured":"Lachmann HJ, Arnold RJG, Gattorno M, Kon\u00e9-Paut I, Ferreira A, K\u00fcmmerle-Deschner J. A retrospective patient Chart Review and Survey in patients with cryopyrin-associated periodic syndromes treated with Anakinra. J Health Econ Outcomes Res. 2013;1(2):123\u201333.","journal-title":"J Health Econ Outcomes Res"},{"issue":"10","key":"3316_CR11","first-page":"2039","volume":"41","author":"M Vasse","year":"2023","unstructured":"Vasse M, Reumaux H, Kon\u00e9-Paut I, Quartier P, Hachulla E. Socio-professional impact and quality of life of cryopyrin-associated periodic syndromes in 54 patients in adulthood. Clin Exp Rheumatol. 2023;41(10):2039\u201343.","journal-title":"Clin Exp Rheumatol"},{"issue":"10","key":"3316_CR12","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1136\/annrheumdis-2020-217419","volume":"79","author":"S Ozen","year":"2020","unstructured":"Ozen S, Ben-Cherit E, Foeldvari I, et al. Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial. Ann Rheum Dis. 2020;79(10):1362\u20139.","journal-title":"Ann Rheum Dis"},{"key":"3316_CR13","doi-asserted-by":"crossref","unstructured":"Jeyaratnam et al. Long-term efficacy and safety of canakinumab in patients with mevalonate kinase deficiency: results from the randomised Phase 3 CLUSTER trial, Rheumatology, 2022, 2088\u20132094.","DOI":"10.1093\/rheumatology\/keab696"},{"key":"3316_CR14","doi-asserted-by":"crossref","unstructured":"Jamilloux Y, Bourdonnay E, Gerfaud-Valentin et al. l. Interleukine-1, inflammasome et maladies auto-inflammatoires. Revue de Medecine Interne 2018; 233\u2013239.","DOI":"10.1016\/j.revmed.2016.07.007"},{"issue":"12","key":"3316_CR15","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1136\/annrheumdis-2013-203666","volume":"73","author":"M Piram","year":"2014","unstructured":"Piram M, Kon\u00e9-Paut I, Lachmann HJ, et al. Validation of the auto-inflammatory diseases activity index (AIDAI) for hereditary recurrent fever syndromes. Ann Rheum Dis. 2014;73(12):2168\u201373.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"3316_CR16","doi-asserted-by":"publisher","first-page":"167","DOI":"10.24953\/turkjped.2020.02.001","volume":"62","author":"M \u00c7akan","year":"2020","unstructured":"\u00c7akan M, Karada\u011f \u015eG, Ayaz NA. Canakinumab in colchicine resistant familial Mediterranean fever and other pediatric rheumatic diseases. Turk J Pediatr. 2020;62(2):167\u201374.","journal-title":"Turk J Pediatr"},{"key":"3316_CR17","first-page":"1703","volume":"27","author":"Y Shinar","year":"2000","unstructured":"Shinar Y, Livneh A, Langevitz P, et al. Genotype-phenotype assessment of common genotypes among patients with familial Mediterranean fever. J Rheumatol. 2000;27:1703\u20137.","journal-title":"J Rheumatol"},{"key":"3316_CR18","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1007\/s00296-014-3205-x","volume":"35","author":"NA Mukhin","year":"2015","unstructured":"Mukhin NA, Kozlovskaya LV, Bogdanova MV, Rameev VV, Moiseev SV, Simonyan A. Predictors of AA amyloidosis in familial Mediterranean fever. Rheumatol Int. 2015;35:1257\u201361.","journal-title":"Rheumatol Int"},{"issue":"Suppl 132","key":"3316_CR19","doi-asserted-by":"publisher","first-page":"30","DOI":"10.55563\/clinexprheumatol\/815tdt","volume":"39","author":"N Atas","year":"2021","unstructured":"Atas N, Eroglu GA, Sodan HN, et al. Long-term safety and efficacy of anakinra and canakinumab in patients with familial Mediterranean fever: a single-centre real-life study with 101 patients. Clin Exp Rheumatol. 2021;39(Suppl 132):30\u20136.","journal-title":"Clin Exp Rheumatol"},{"issue":"11","key":"3316_CR20","doi-asserted-by":"publisher","first-page":"3324","DOI":"10.1093\/rheumatology\/keaa121","volume":"59","author":"E Sag","year":"2020","unstructured":"Sag E, Akal F, Atalay E, et al. Anti-IL1 treatment in colchicine-resistant paediatric FMF patients: real life data from the HELIOS registry. Rheumatology (Oxford). 2020;59(11):3324\u20139.","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"3316_CR21","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1007\/s00296-022-05199-w","volume":"42","author":"Y Karabulut","year":"2022","unstructured":"Karabulut Y, Gezer HH, \u00d6z N, Esen \u0130, Duru\u00f6z MT. Real-life data on tapering or discontinuation of canakinumab therapy in patients with familial Mediterranean fever. Rheumatol Int. 2022;42(12):2211\u20139.","journal-title":"Rheumatol Int"},{"issue":"Suppl 132","key":"3316_CR22","doi-asserted-by":"publisher","first-page":"118","DOI":"10.55563\/clinexprheumatol\/ef5llq","volume":"39","author":"B S\u00f6zeri","year":"2021","unstructured":"S\u00f6zeri B, S\u00f6nmez HE, Karada\u011f \u015eG, et al. The feasibility of withdrawing canakinumab in paediatric colchicine-resistant familial Mediterranean fever patients. Clin Exp Rheumatol. 2021;39(Suppl 132):118\u201323.","journal-title":"Clin Exp Rheumatol"},{"key":"3316_CR23","doi-asserted-by":"crossref","unstructured":"Sener S, Cam V, Batu ED et al. Feasibility of canakinumab withdrawal in colchicine-resistant familial Mediterranean fever [published online ahead of print, 2023 Mar 24]. Rheumatology (Oxford). 2023;kead128.","DOI":"10.1093\/rheumatology\/kead128"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-024-03316-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-024-03316-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-024-03316-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T02:05:43Z","timestamp":1712541943000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-024-03316-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,8]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3316"],"URL":"https:\/\/doi.org\/10.1186\/s13075-024-03316-7","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,8]]},"assertion":[{"value":"11 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"IKP has received consulting fees, speaking fees and\/or honoraria Novartis, SOBI, LFB, Abbvie, Pfizer, Chugai, Amgen, Zydus. SG has received consulting fees, speaking fees and\/or honoraria from Novartis and SOBI. AB has received research grant from Boehringer Ingelheim and Merck Serono and consulting fees from Novartis, Abbvie, GSK, Roche Chugai. MJ is an employee of Novartis. MP is an employee of I&M STAT working for Novartis. LL has received consulting fees from Novartis. PP has received consulting fees, speaking fees and\/or honoraria from Novartis and SOBI. VH has received consulting fees, speaking fees and\/or honoraria from Novartis, SOBI and MSD vaccin.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Patients were enrolled after confirmation that they (or their legal guardian) were not opposed to the study and the storage of their personal data. The JIR cohort protocol was approved by the French Ethics Committee (CCTIRS) and by the National Commission of data processing and liberties (CNIL).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"80"}}